Daratumumab 및 BCMA 표적 치료 후 재발한 다발성 골수종에서 SAR442257 항-CD38 삼중 특이성 T 세포 결합제의 생체외 효능 보조 그림 3

Keller 등(Tue,)이 이 질문을 연구하였다.

www.synapsesocial.com/papers/68e746dfb6db6435876c00ba — DOI: https://doi.org/10.1158/2767-9764.25392858

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Supplementary Figure 3 from <i>Ex Vivo</i> Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies· 2024
2. Supplementary Figure 2 from <i>Ex Vivo</i> Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies· 2024
3. Supplementary Figure 2 from <i>Ex Vivo</i> Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies· 2024
4. Supplementary Figure 1 from <i>Ex Vivo</i> Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies· 2024
5. Supplementary Figure 1 from <i>Ex Vivo</i> Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies· 2024